PT - JOURNAL ARTICLE AU - Adenaiye, Oluwasanmi O. AU - Lai, Jianyu AU - de Mesquita, P. Jacob Bueno AU - Hong, Filbert AU - Youssefi, Somayeh AU - German, Jennifer AU - Tai, S.-H. Sheldon AU - Albert, Barbara AU - Schanz, Maria AU - Weston, Stuart AU - Hang, Jun AU - Fung, Christian AU - Chung, Hye Kyung AU - Coleman, Kristen K. AU - Sapoval, Nicolae AU - Treangen, Todd AU - Berry, Irina Maljkovic AU - Mullins, Kristin AU - Frieman, Matthew AU - Ma, Tianzhou AU - Milton, Donald K. AU - , TI - Infectious SARS-CoV-2 in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection AID - 10.1101/2021.08.13.21261989 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.13.21261989 4099 - http://medrxiv.org/content/early/2021/08/13/2021.08.13.21261989.short 4100 - http://medrxiv.org/content/early/2021/08/13/2021.08.13.21261989.full AB - Background SARS-CoV-2 epidemiology implicates airborne transmission; mask source-control efficacy for, variant impact on, and infectiousness of aerosols are not well understood.Methods We recruited COVID-19 cases to give blood, saliva, mid-turbinate and fomite (phone) swabs, and 30-minute breath samples while vocalizing into a Gesundheit-II, with and without masks at up to two visits two days apart. We quantified and sequenced viral RNA, cultured virus, and assayed sera for anti-spike and anti-receptor binding domain antibodies.Results We enrolled 61 participants with active infection, May 2020 through April 2021. Among 49 seronegative cases (mean days post onset 3.8 ±2.1), we detected SARS-CoV-2 RNA in 45% of fine (≤5 µm), 31% of coarse (>5 µm) aerosols, and 65% of fomite samples overall and in all samples from four alpha variant cases. Masks reduced viral RNA by 48% (95% confidence interval [CI], 3 to 72%) in fine and by 77% (95% CI, 51 to 89%) in coarse aerosols. The alpha variant was associated with a 43-fold (95% CI, 6.6 to 280-fold) increase in fine aerosol viral RNA that remained a significant 18-fold (95% CI, 3.4 to 92-fold) increase adjusting for viral RNA in saliva, in mid-turbinate swabs, and other potential confounders. Two fine aerosol samples, collected days 2-3 post illness onset, while participants wore masks, were culture-positive.Conclusion SARS-CoV-2 is evolving toward more efficient airborne transmission and loose-fitting masks provide significant but only modest source control. Therefore, until vaccination rates are very high, continued layered controls and tight-fitting masks and respirators will be necessary.Key PointsCases exhale infectious viral aerosols.SARS-CoV-2 is evolving toward more efficient airborne transmission.Loose-fitting masks significantly but moderately reduce viral RNA aerosol.Tight-fitting masks or respirators and ventilation/air cleaning are essential for worker protection in public-facing or crowded indoor workplaces.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementMaterial has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The investigators have adhered to the policies for protection of human subjects as prescribed in AR 70–25. The View(s) expressed are those of the authors and do not necessarily reflect the official views of the Department of Health and Human Services, the Departments of the Army, Navy or Air Force, the Department of Defense, or the U.S. Government. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position or policy of these agencies and no official endorsement should be inferred. This work was supported by Prometheus–UMD, sponsored by the Defense Advanced Research Projects Agency (DARPA) BTO under the auspices of Col. Matthew Hepburn through agreement N66001–18–2–4015. This work was also supported by the National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance (CEIRS), Grant Number HHSN272201400008C, the Centers for Disease Control and Prevention, Contract Number 200-2020-09528. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position or policy of these funding agencies and no official endorsement should be inferred. This work was also supported by a grant from the Bill & Melinda Gates Foundation, and a generous gift from The Flu Lab (https://theflulab.org). The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Maryland Institutional Review Board and the Human Research Protection Office of the Department of the Navy.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified data and code for the accepted manuscript will be made available on github.